Camizestrant
-
{
- All
- News
-
Advanced Breast Cancer Drug Fails Key Clinical Trial Days After Regulatory Approval
The SERENA-4 trial included 1,371 patients with previously untreated advanced hormone receptor-positive, HER2-negative breast cancer. Researchers compared camizestrant plus Ibrance with Ibrance and standard hormone-lowering treatment.
-
First-Ever Breast Cancer Drug Guided By Blood Tests Before Scans Show Progression Approved By Regulator
Camizestrant received accelerated approval, meaning additional studies are required to confirm its clinical benefit. The FDA has specifically stated that continued approval may depend on confirmatory evidence.
-
Advanced Breast Cancer Drug Fails Key Clinical Trial Days After Regulatory Approval
The SERENA-4 trial included 1,371 patients with previously untreated advanced hormone receptor-positive, HER2-negative breast cancer. Researchers compared camizestrant plus Ibrance with Ibrance and standard hormone-lowering treatment.
-
First-Ever Breast Cancer Drug Guided By Blood Tests Before Scans Show Progression Approved By Regulator
Camizestrant received accelerated approval, meaning additional studies are required to confirm its clinical benefit. The FDA has specifically stated that continued approval may depend on confirmatory evidence.
